Home > Article > Latest Developments in Cellular Therapy for Multiple Myeloma
Multiple Myeloma
Read Time: < 1 min

Latest Developments in Cellular Therapy for Multiple Myeloma

Published Online: December 23rd 2020 Oncology & Hematology Review (US). 2020;16(2):Online ahead of journal publication
Authors: Tara K Gregory, Henning Schade, Jesús G Berdeja
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Novel drugs and continuous therapy have improved outcomes in patients with multiple myeloma (MM), however current therapies are largely non-curative with diminishing durations of response with subsequent therapies. Cellular therapies including chimeric antigen receptor (CAR) T cells have started to illustrate deeper and longer durations of relapse in the relapsed/refractory (RR) population. Current research seeks to expand on the durability of response, novel combinations and targets as well as the timing of CAR T in the treatment schema. This review summaries the updates in cellular therapy for MM.

Keywords

Multiple myeloma, chimeric antigen receptor T cells, BCMA

Article:

**This manuscript has been accepted for publication, but not yet copyedited or typeset, and may be subject to minor changes during the production process**

Article Information:
Disclosure

For all authors: Research Funding: all >10k
Tara K. Gregory’s institution receives research funds in her name from the following: Abbvie, Amgen, Acetylon, Bluebird, BMS, Celgene, Celularity, Constellation, CRISP Therapeutics, CURIS, EMD Sorono, Genentech, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, Vivolux

For Dr. Berdeja: Consultancy: all <10k
Institution received consultancy payments from the following: Amgen, BioClinica, BMS, Celgene, CRISPR Therapeutics, Janssen, Karyopharm, Kite Pharma, Legend, Prothena, SecuraBio, Servier, Takeda

Compliance With Ethics

This article involves a review of the MM CAR T cell therapy via a PUBMED literature review, recent presentations at medical conferences and ongoing research at ClinicalTrials.gov. It did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.

Authorship

The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Correspondence

Tara K Gregory, Sarah Cannon Research Institute, Denver, CO, USA.
E: tara.gregory@healthonecares.com

Support

No funding was received in the publication of this article.

Open Access

This article is freely accessible at touchONCOLOGY.com © Touch Medical Media 2020.

Received

2020-07-09

Further Resources

Share this Article
Related Content In Multiple Myeloma
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar